A novel therapeutic approach for LPIN1 mutation-associated rhabdomyolysis--The Austrian experience

Area of Science:

• Pediatric Endocrinology
• Genetic Metabolic Disorders
• Muscle Physiology

Background:

• Lipin 1 gene (LPIN1) mutations are a significant cause of pediatric rhabdomyolysis, leading to cellular energy deficiency.
• Rhabdomyolysis episodes associated with LPIN1 mutations have a poor prognosis due to limited treatment options.
• A novel therapeutic strategy focusing on preventing and treating catabolism is proposed.

Purpose of the Study:

• To evaluate the efficacy of a therapeutic strategy involving high caloric intake and early glucose treatment for pediatric patients with LPIN1 mutations.
• To assess the impact of this strategy on the frequency and duration of rhabdomyolysis episodes.

Main Methods:

• Five pediatric patients with diagnosed LPIN1 mutations were enrolled.
• Patients received instructions for maintaining high caloric intake during potential catabolic situations (e.g., infections, physical activity).
• Intravenous high-concentration glucose was administered at the onset of rhabdomyolysis symptoms.

Main Results:

• The implemented therapeutic strategies successfully limited the occurrence of rhabdomyolysis episodes.
• The duration of rhabdomyolysis episodes was reduced to 5 days, compared to the 7-10 days reported in existing literature.
• These findings suggest a positive response to the preventative and early treatment approach.

Conclusions:

• The study indicates that a preventative approach and early treatment of catabolism benefit pediatric patients with LPIN1 mutations.
• This strategy appears to mitigate the severity and frequency of rhabdomyolysis episodes in affected children.
• Further research with larger cohorts is warranted to confirm these promising preliminary findings.